Charles J. Fisher Jr. - 10 Feb 2022 Form 4 Insider Report for AETHLON MEDICAL INC (AEMD)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AEMD
Reported as of: 10 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Feb 2022, 12:54:07 UTC
Prior SEC filing: 30 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ James B. Frakes, Attorney-in-Fact

Key filing fact

Charles J. Fisher Jr. filed Form 4 for AETHLON MEDICAL INC (AEMD) on 11 Feb 2022.

Key facts

This page summarizes Charles J. Fisher Jr.'s Form 4 filing for AETHLON MEDICAL INC (AEMD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2022, 12:54.

Change

Previous filing in this sequence was filed on 30 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AEMD transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +192,600
Change %
Price: $0.000000
Shares after: 192,600
Date: 10 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 192,600
Exercise price: $1.41
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the stock option shall vest and become exercisable on February 10, 2023, and the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter.